In some embodiments, the otic formulation or composition contains at least one viscosity modulating agent that provides the otic formulation or composition with a viscosity of at least about 10 cP, about 20 cP, about 30 cP, about 40 cP, about 50 cP, about 60 cP, about 70 cP, about 80 cP, about 90 cP, about 100 cP, about 200 cP, about 300 cP, about 400 cP, about 500 cP, about 600 cP, about 700 cP, about 800 cP, about 900 cP, about 1000 cP, about 2,000 cP, about 3,000 cP, about 4,000 cP, about 5,000 cP, about 6,000 cP, about 7,000 cP, about 8,000 cP, about 9,000 cP, about 10,000 cP, about 15,000 cP, or about 20,000 cP
Muscle preservation focus only: Ipamorelin alone for clean GH support, or Ipamorelin + CJC-1295 for enhanced effects
In the United States, neither peptide has received approval from the Food and Drug Administration (FDA) for human therapeutic use as prescription medications
Acknowledgements This work was financially supported by the German Research Foundation (Collaborative Research Centre 1112, Project C02 to MSK, C05 to JL, and Z01 to NM, MSK, and BK